Simcere Pharmaceutical Group. has filed a patent for a composition containing edaravone and dexborneol to treat cerebral stroke in patients with a history of hypertension. The method involves administering the composition to patients in need of treatment. GlobalData’s report on Simcere Pharmaceutical Group gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Simcere Pharmaceutical Group, Cancer treatment biomarkers was a key innovation area identified from patents. Simcere Pharmaceutical Group's grant share as of January 2024 was 38%. Grant share is based on the ratio of number of grants to total number of patents.
A patent application (Publication Number: US20240033247A1) discloses a method for treating cerebral stroke by administering a composition containing edaravone and dexborneol to patients with a history of hypertension. The weight ratio of edaravone to dexborneol in the composition can range from 1:1 to 8:1, with a preferred ratio of 4:1. The composition is typically administered 1-3 times a day for 3-21 consecutive days, with a dosage of 10-30 mg/dose of edaravone. Additionally, the composition may include a pharmaceutically acceptable adjuvant such as sodium metabisulfite, propylene glycol, or water for injection.
Furthermore, the method specifies that the cerebral stroke being treated is typically an ischemic stroke, including acute ischemic stroke. Upon administration of the composition, the plasma exposure ratio of edaravone to dexborneol in the patient is maintained within the range of 1:1 to 8:1 or 1:1 to 5:1. This method provides a detailed protocol for the treatment of cerebral stroke using a specific combination of edaravone and dexborneol, highlighting the importance of dosage, frequency of administration, and the ratio of the two components in the composition. The patent application aims to offer a novel and potentially effective treatment option for patients in need of cerebral stroke management, particularly those with a history of hypertension.
To know more about GlobalData’s detailed insights on Simcere Pharmaceutical Group, buy the report here.
See Also:
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
